



#13 1646  
RECEIVED  
SEP 26 2002

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: CROZE et al

Serial No.: 09/881,050

Group Art Unit: Unassigned

Filed: June 15, 2001

Examiner: Unassigned

For: NOVEL INTERFERON FOR THE TREATMENT IF MULTIPLE SCLEROSIS

TECH CENTER 1600/2900

**INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §§ 1.56, 1.97 and 1.98**

Assistant Commissioner for Patents  
Washington, D. C. 20231

Sir:

This Information Disclosure Statement is made in accordance with 37 C.F.R. §§ 1.56, 1.97 and 1.98 as follows:

**TIMING AND FEES**

Under 37 C.F.R. § 1.97(b), no fee or statement is required:

Within three months of the filing date of a national application other than a CPA under § 1.53(d); OR

Within three months of the date of entry of the national stage of an international;

Before the mailing of a first Office Action on the merits after filing a RCE; or

Before the mailing of a first Office Action on the merits.

No fee or statement is required.

Under 37 C.F.R. § 1.97(c):

After the periods specified in 37 C.F.R. § 1.97(b), but before the mailing date of either:

A Final Action or under 37 C.F.R. 1.113; OR

A Notice of Allowance under 37 C.F.R. § 1.311; and

is accompanied by: (check one)

The statement as specified in 37 C.F.R. § 1.97(e) set out below; OR

A check covering the fee of \$180.00 under 37 C.F.R. § 1.17(p).

Under 37 C.F.R. § 1.97(d):

RECEIVED

After the mailing date of either:

SEP 26 2002

- a Final Action or under 37 C.F.R. § 1.113; OR
- a Notice of Allowance under 37 C.F.R. § 1.311;

TECH CENTER 1600/2900

BUT is filed on or before payment of the Issue Fee; AND is accompanied by:

- The statement as specified in 37 C.F.R. § 1.97(e) as set forth below, and the Petition fee of \$130.00 set out in 37 C.F.R. § 1.17(p).

Statements Under 37 C.F.R. 1.97(e)

- Each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing date of this Information Disclosure Statement; or
- No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and to the knowledge of the undersigned Attorney after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any prior individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing date of the Information Disclosure Statement.

Cited Materials

- Copies of materials listed but not attached were cited in parent application Serial No. \_\_\_\_; see 37 C.F.R. § 1.98(d).
- Copies of materials listed but not attached were cited in an International Search Report dated August 22, 2002; receipt of the International Search Report and copies of references was confirmed by the PCT International Division of the U.S. PTO in the Notice of Acceptance mailed \_\_\_\_.

Non-English Language References

- The reference(s): \_\_\_\_ in the English-language is (are) indicated by commercial data bases to correspond to the reference(s): \_\_\_\_ , respectively.
- (An) English-language translation(s) of the references: \_\_\_\_ is (are) provided.
- A commercial English-language abstract of reference(s) \_\_\_\_ is (are) provided.
- An English-language search report or an equivalent paper from a foreign patent office is provided indicating the relevance of the cited reference(s).
- A foreign-language search report from a foreign patent office is provided.

Pertinent parts are translated below:

X = document of particular relevance when it is taken alone  
Y = document of particular relevance when it is combined with another such document  
A = document defining the general state of the art  
O = non-written disclosure  
P = intercalated document  
T = document cited to understand the theory or principle underlying the invention  
E = patent document which has the benefit of a date earlier to the filing date and which was published only on this filing date or only on a later date  
D = cited in the application  
L = cited for another reason

Additional Information


Payment of Fees Due (If Any):

A check for \$ covering the fee identified above is attached.

Please charge to Deposit Account No. 13-3402 \$ for the fee identified above.

The Commissioner is hereby authorized to charge or credit any overpayment to Deposit Account #13-3402, two copies of this paper are attached for this purpose.

Respectfully submitted,



Brion P. Heaney Reg. No. 32,542  
Attorney/Agent for Applicants

MILLEN, WHITE, ZELANO  
& BRANIGAN, P.C.  
Arlington Courthouse Plaza 1  
2200 Clarendon Blvd. Suite 1400  
Arlington, Virginia 22201  
Telephone: (703) 243-6333  
Facsimile: (703) 243-6410

Attorney Docket No.: Berlx-88

Date: September 25, 2002

BPH/cas

K:\Berlx\88\Information Disclosure Statement - New.doc